Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgM

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    287 result(s) found for: IgM. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-001545-20 Sponsor Protocol Number: mRNA-1647-P104 Start Date*: 2024-05-09
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age...
    Medical condition: Cytomegalovirus infection
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-010955-29 Sponsor Protocol Number: 10031983 Start Date*: 2009-07-13
    Sponsor Name:Division of Clinically Immunology and Rheumatology, AMC
    Full Title: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
    Medical condition: Pre-clinical RA patients with a high risk on developing the disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001118-40 Sponsor Protocol Number: NL69183.xxx.19 Start Date*: 2019-08-22
    Sponsor Name:Department of Pulmonology
    Full Title: Response to pneumococcal polysaccharide vaccination in healthy adults
    Medical condition: immunodeficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001613-33 Sponsor Protocol Number: IgM-FAT Start Date*: 2019-04-18
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose in patients with septic shock. A multicenter, intervention...
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040580 Shock septic LLT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001901-18 Sponsor Protocol Number: LGS.MMR.01.2016.2022 Start Date*: 2017-02-14
    Sponsor Name:The Danish National University Hospital "Rigshospitalet"
    Full Title: Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting
    Medical condition: Infection with measles, mumps or rubella
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036654 Prevention LLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000067-23 Sponsor Protocol Number: PN-1007-001 Start Date*: 2020-09-21
    Sponsor Name:Polyneuron Pharmaceuticals AG
    Full Title: First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients
    Medical condition: anti-MAG neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066137 Anti-MAG neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001663-22 Sponsor Protocol Number: na Start Date*: 2018-09-05
    Sponsor Name:Maastricht University
    Full Title: Effects of ciprofibrate on myocardial insulin sensitivity in pre-diabetes
    Medical condition: Insulin resistance, diastolic cardiac failure, mitochondrial function
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000048-10 Sponsor Protocol Number: CCAD106A2101 Start Date*: 2005-04-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolera...
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004998-53 Sponsor Protocol Number: OMB116024 Start Date*: 2013-02-05
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia.
    Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022380-35 Sponsor Protocol Number: 982 Start Date*: 2011-06-10
    Sponsor Name:Biotest AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in ...
    Medical condition: severe Community Acquired Pneumonia (sCAP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006051-17 Sponsor Protocol Number: mRNA-1647-P301 Start Date*: Information not available in EudraCT
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Year...
    Medical condition: Prevention of Cytomegalovirus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10072247 Cytomegalovirus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018095-33 Sponsor Protocol Number: 2009-40 Start Date*: 2010-03-08
    Sponsor Name:Institut Pasteur
    Full Title: Evaluation d’outils de diagnostic sérologique discriminant une infection naturelle par le virus amaril d’une vaccination anti-amarile
    Medical condition: réponse au vaccin anti-amaril chez des sujets adultes sains
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048240 Yellow fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006172-16 Sponsor Protocol Number: CoVVacBoost Start Date*: 2021-11-26
    Sponsor Name:Medical University of Graz
    Full Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study
    Medical condition: Covid (Coronavirus disease)- 19 immunisation
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002345-42 Sponsor Protocol Number: 998 Start Date*: 2020-08-26
    Sponsor Name:Biotest AG
    Full Title: A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with...
    Medical condition: Severe Corona Virus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001563-21 Sponsor Protocol Number: IM-T-hLL2-18 Start Date*: 2005-02-02
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003887-21 Sponsor Protocol Number: 0802/SM Start Date*: 2010-01-21
    Sponsor Name:Univ.-Doz. Dr. Karl-Heinz Smolle
    Full Title: Klinische Studie zur Überprüfung des Einflusses einer intradialytischen Verabreichung von Vitamin E und Vitamin C auf biochemische Indikatoren für die antioxidative Kapazität sowie auf Entzündungsm...
    Medical condition: Akutes Nierenversagen und Sepsis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002186-17 Sponsor Protocol Number: volgt Start Date*: 2021-08-31
    Sponsor Name:RadboudUMC
    Full Title: Timing and sequence of vaccination against COVID-19 and Influenza
    Medical condition: Immunogenicity of the consecutive vaccination with both an mRNA COVID-19 vaccin and Influenza vaccin, in different sequences
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000182-33 Sponsor Protocol Number: 76421 Start Date*: 2021-03-25
    Sponsor Name:Radboudumc
    Full Title: Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers
    Medical condition: Immunogenicity of the mRNA BNT162b2 COVID-19 vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002711-94 Sponsor Protocol Number: HO124WM Start Date*: 2014-09-19
    Sponsor Name:HOVON Foundation
    Full Title: HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10054697 Waldenstrom's macroglobulinemia recurrent LLT
    21.1 100000004864 10054698 Waldenstrom's macroglobulinemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002182-38 Sponsor Protocol Number: 2015/074/HP Start Date*: 2015-09-28
    Sponsor Name:CHU - Hôpitaux de Rouen
    Full Title: Study of the Plaquenil® efficacy on the endothelial dysfunction and its vascular consequences during the antiphospholipid syndrom
    Medical condition: Patients must meet the classification criteria for arterial antiphospholipids syndrom. They must have had a confirmed episode of arterial thrombosis and the presence of 2 tests performed at 12 week...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 09:50:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA